3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Dermatologic
1
Conditions
Melanoma
13
Colorectal Neoplasms
5
Neoplasm Metastasis
4
Neoplasms
2
Lung Neoplasms
2
Carcinoma, Non-Small-Cell Lung
2
Brain Neoplasms
2
Solid Tumors Harboring a BRAF V600 Mutation
1
Skin Neoplasms
1
Skin Diseases
1
Pancreatic Neoplasms
1
Lymphatic Metastasis
1
Hematologic Neoplasms
1
Gliosarcoma
1
Glioma
1
Glioblastoma
1
Astrocytoma
1
Advanced BRAF Mutant Cancers
1
Interventions
binimetinib
2
ipatasertib
1
exemestane
1
encorafenib
1
baricitinib
1
atezolizumab
1
Vemurafenib
1
VP-102
1
Paclitaxel
1
Fluorouracil
1
Everolimus
1
Dacarbazine
1
Cantharidin
1
BF-200 ALA
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Has results
×
Skin Diseases
×
encorafenib
×
Clear all
NCT01909453
2026-02-27
COLUMBUS
Pfizer
Phase 3
Completed
921 enrolled
48 charts
1 FDA